State Council: Imported anti-cancer drugs starting from May 1 are all zero-tariff

Medical Network April 13 hearing Just now, the State Council executive meeting decided that from May 1st, imported anti-cancer drugs are all implemented zero tariff!

The Premier of the State Council presided over the executive meeting of the State Council on April 12 and decided to impose zero tariff on imported anticancer drugs and encourage the import of innovative drugs.

In order to reduce the drug burden on patients, especially cancer patients, and have more medication options, the meeting decided:

First, from May 1st, 2018, all ordinary people, including cancer drugs, will be included. drug , The import tariffs of alkaloids with anti-cancer effects and those of Chinese patent medicines that have actually been imported are reduced to zero, so that all the anti-cancer drugs actually imported by China will realize zero tariffs. The production of anti-cancer drugs will be greatly reduced, and the import value-added tax will be reduced. negative.

The second is to step up to study comprehensive measures and adopt government concentration purchase , Incorporate imported innovative drugs, especially urgently needed anti-cancer drugs into the medical insurance reimbursement list, and research and utilize cross-border e-commerce channels, and take measures to eliminate various unreasonable price increases in circulation, so that people can really feel the need for anti-cancer drugs. The price has decreased significantly.

The third is to speed up the importation and listing of innovative drugs. The application of clinical trials from the approval system to the expiration of the default system, to import chemical drugs instead enterprise The result of the inspection is cleared, and the batch inspection is no longer mandatory.

The fourth is to strengthen the protection of intellectual property rights. To set up a period of data protection of up to six years for innovative chemical drugs, and not to approve the listing of similar products during the protection period. To compensate for the patent protection period of up to five years for innovative drugs that are applied simultaneously for listing in China and overseas. .

Fifth, strengthen the quality supervision, strengthen the on-site production inspection of imported drugs, and strictly crack down on false sales.

In addition to the zero-tariff of the imported anticancer drugs proposed by the prime minister, the executive meeting also proposed to incorporate imported anti-cancer drugs into health insurance in a timely manner to speed up the time-to-market, set up data protection periods and compensation for patent protection, and strictly fight production and sales. Counterfeit medicine 4 favorable policies for importing anti-cancer drugs.

In 2015, the size of the Chinese oncology drug market was close to 100 billion yuan. The average annual growth rate exceeded 17% in the previous six years. In 2017, the oncology drug market exceeded 120 billion yuan.

All along, China's oncology drug market is dominated by imported pharmaceutical companies, such as Roche, Sanofi, Novartis, Pfizer, Lilly and others.

At present, according to the latest tariff rate adjustment of the Ministry of Finance in 2017, the most-favoured-nation tariff rate for imported drugs in China is 2%-4%, while the highest average rate is 80%, plus VAT 17%.

Obviously, on the one hand, reducing the import tax rate for such drugs to 0 will help increase the availability of drug use for patients, thus increasing the market share of imported anticancer drugs.

On the other hand, accelerating the pace of approval will also help pharmaceutical companies to seize the market as soon as possible. Only with these two points combined with the vast Chinese market, for any company there is no doubt that there is no small attraction.

According to statistics compiled by Cypress's author, Xinhua, 8 out of the top 20 oncology drugs in the world have not been listed in China in 2017, and there are less than one month's time for new drugs. standard Will be implemented. By then, the speed of import of anti-cancer drugs in China will be greatly accelerated!

Note: According to Rubik's Cube and CFDA batch library, for reference.

According to the Nanjing Shenghe Pharmaceutical IPO prospectus, in 2015, China's cancer medicine market reached 25.4 billion yuan, accounting for only 25.4% of the tumor market in the same period.

Once zero-tariff imported international anti-cancer drugs enter the Chinese market, the market share of traditional Chinese patent medicines will have to face severe challenges!